An abbreviated excerpt of the model’s rationale highlights complementary mechanisms: “...distinct mechanisms of actions targeting different molecular pathways involved in cancer progression...By targeting FOLR1, mirvetuximab soravtansine can disrupt the folate metabolism pathway and inhibit cell division, making the cancer cells more susceptible to chemotherapy...By inhibiting VEGF, bevacizumab can prevent the formation of new blood vessels, starving the tumor of nutrients and oxygen, and enhancing the efficacy of chemotherapy. Here, VEGFA is linked to cancer.